Inger Marie S. Dahl

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life

Eva Hellström‐Lindberg, Nina Gulbrandsen, Greger Lindberg et al. · British Journal of Haematology · 2003 · 454 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

Eva Hellström-Lindberg, Tomas Ahlgren, Yves Béguin et al. · Blood · 1998 · 306 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Serum syndecan-1: a new independent prognostic marker in multiple myeloma

Carina Seidel, Anders Sundan, Martin Hjorth et al. · Blood · 2000 · 241 citations

Medicine, Oncology, Pathology +16

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

Anders Waage, Peter Gimsing, Peter Fayers et al. · Blood · 2010 · 231 citations · Full text

Medicine, Hematology, Oncology +13

Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors

Thomas Rasmussen, Michael Kuehl, Marianne Lodahl et al. · Blood · 2004 · 162 citations · Full text

Medicine, Genetics, Oncology +14